

Policies Repository



Policy Title Cyclooxygenase-2 (COX-2) Inhibitors and Meloxicam (Mobic®)

Policy Number FS.CLIN.36

Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product line, group or contract. Some medications may be subject to precertification, age, gender or quantity edits. Individual member benefits must be verified.

This Pharmacy Policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety or FDA approval may have changed. If the Medical/Pharmacy Reviewer is aware of any new information on the subject of this document, please provide it promptly to the Medical/Pharmacy Policy Department. This information may include new FDA approved indications, withdrawals or other FDA alerts. This type of information is relevant not only when considering whether this Policy should be updated, but also when applying it to current requests for coverage.

Members are advised to use participating pharmacies in order to receive the highest level of benefits.

Policy **Cyclooxygenase-2 (COX-2) inhibitors** can be used to treat various pain disorders in individuals who cannot tolerate, or who have contraindications to, non-selective non-steroidal anti-inflammatory drugs (NSAIDs). **Meloxicam (Mobic®)**, a preferential inhibitor of the COX-2 enzyme, is indicated to treat the signs and symptoms of osteoarthritis and a variety of other pain disorders.

The use of all COX-2 inhibitors and meloxicam (Mobic®) require prior authorization (ie, clinical pharmacy and/or Medical Director review).

Policy Description **Cyclooxygenase-2 (COX-2) inhibitors and meloxicam (Mobic®)** fall into a broad class of agents called non-steroidal anti-inflammatory drugs (NSAIDs). Since COX-2 inhibitors bind selectively to the COX-2 enzyme and not the COX-1 enzyme, these drugs are unique from traditional NSAIDs. Meloxicam (Mobic®), a preferential inhibitor of the COX-2 enzyme, exhibits greater inhibitory activity against COX-2 than COX-1; its selectivity is claimed to confer a lower propensity for adverse gastrointestinal effects compared with traditional NSAIDs.

Blocking the COX-2 enzyme has been shown to impede the production of the chemical messengers (prostaglandins) that cause the pain and swelling associated with arthritis inflammation.

Policy Guideline Inclusion CELECOXIB (CELEBREX®)
Celecoxib (Celebrex®) is approved when **one** of the following inclusion criteria is met:

- Documentation of familial adenomatous polyposis (FAP)
- Documentation of the failure of a meloxicam-containing product and one of the following:
 - Documentation of the trial and failure of two additional non-steroidal anti-inflammatory drugs (NSAIDs)
 - Documentation that the individual is 65 years of age or older
 - Documentation of concurrent warfarin use (within the last 90 days)
 - Documentation of a bleeding disorder
 - Documentation of concurrent systemic steroid treatment
- Documentation of a history of gastrointestinal bleed, peptic ulcer, gastroesophageal reflux disease (GERD), or Barrett's esophagus.
- Documentation of a concomitant condition in which celecoxib (Celebrex®) offers a significant advantage over non-COX-2

selective NSAIDs and meloxicam (Mobic®).

MELOXICAM (MOBIC®)

Brand meloxicam (Mobic®) is approved when the following inclusion criterion is met:

- Documentation of trial and failure or contraindication to generic meloxicam.

Policy Guideline Exclusion

CELECOXIB (CELEBREX®)

Celecoxib (Celebrex®) is denied when **all** of the following exclusion criteria are present:

- No documentation of familial adenomatous polyposis (FAP)
- No documentation of a failure of a meloxicam-containing product and one of the following:
 - No documentation of trial and failure of two additional NSAIDs
 - No documentation that the individual is 65 years of age or older
 - No documentation of concurrent warfarin use (within the last 90 days)
 - No documentation of a bleeding disorder
 - No documentation of concurrent systemic steroid treatment
- No documentation of a history of gastrointestinal bleed, peptic ulcer, GERD, or Barrett's esophagus
- Documentation of a sulfa allergy (A sulfa allergy is exclusionary for celecoxib [Celebrex®]); documentation of a tolerated trial of sulfa is required for approval.)
- Documentation of an aspirin/NSAID allergy
- No documentation of a concomitant condition in which celecoxib (Celebrex®) offers a significant advantage over non-COX-2 selective NSAIDs and meloxicam (Mobic®) MELOXICAM (MOBIC®)

MELOXICAM (MOBIC®)

Brand meloxicam (Mobic®) is denied when **any** of the following exclusion criteria are present:

- No documentation of trail and failure or contraindication to generic meloxicam
- Documentation of an aspirin/NSAID allergy

Policy List of Applicable Drugs

Drug	Osteoarthritis	Rheumatoid Arthritis	Primary Dysmenorrhea	Acute Pain	Familial Adenomatous Polyposis (FAP)	Migraines	Exclude if Sulfa Allergy Exists	Exclude if Non-steroidal Anti-inflammatory Drugs (NSAIDs) or Aspirin Allergy
Celebrex®	X	X	X	X	X		X	X
Mobic®	X	X		X				X

COX-2 Inhibitors	
Brand Name	Generic Name
Celebrex	celecoxib

Preferential Inhibitor of COX-2

Brand Name	Generic Name
Mobic	meloxicam

Dosing and Administration

Refer to the specific manufacturer's prescribing information for administration and dosage details, contraindications, and Black Box warnings.

Policy References

Celebrex® [package insert]. New York, NY: Pfizer; 2006. [Celebrex Web site]. 07/27/07. Available at: http://pfizer.com/files/products/uspi_celebrex.pdf. Accessed February 19, 2009.

Celebrex®. Drug facts and comparisons. [Facts & Comparisons Web site]. 03/22/02. Available at: <http://www.factsandcomparisons.com/efacts.asp?> [via subscription only]. Accessed February 19, 2009.

Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group (Meloxicam Large-Scale International Study Safety Assessment). *Br J Rheumatol*. 1998;37(9):937-945.

Layton D, Hughes K, Harris S, Shakir SA. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. *Rheumatology (Oxford)*. 2003;42(11):1332-1341.

Meloxicam (Mobic®). In: *DrugPoints* [online through STAT! Ref]. Greenwood Village, CO: Thomson Micromedex; 2006. Available at: <http://www.thomsonhc.com> [via subscription only]. Accessed February 19, 2009.

Mobic® [prescribing information]. Columbus, OH: Boehringer Ingelheim Roxane, Inc.; 2008. Also available online at: <http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Mobic/MobicTabs7-5-15mg.PDF>. Accessed February 19, 2009.

Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. *Am J Med*. 2004;117(2):100-106.

Turck D, Su C, Heinzl G, et al. Lack of interaction between meloxicam and warfarin in healthy volunteers. *Eur J Clin Pharmacol*. 1997;51(5):421-425.

US Food and Drug Administration (FDA). FDA News. FDA approves first generic meloxicam. [FDA Web site]. 07/19/06. Available at: <http://www.fda.gov/bbs/topics/NEWS/2006/NEW01412.html>. Accessed February 19, 2009.

Yocum D, Fleischmann R, Dalgin P, et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: A 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. *Arch Int Med*. 2000;160(19):2947-2954.

Policy Link to Related Policies

Printed

05/04/2009 10:12:13

The Policy Bulletins on this web site were developed to assist Independence Blue Cross and its subsidiaries ("IBC") in administering the provisions of the respective benefit programs, and do not constitute a contract. If you are an IBC member, please refer to your specific benefit program for the terms, conditions, limitations and exclusions of your coverage. IBC does not provide health care services, medical advice or treatment, or guarantee the outcome or results of any medical services/treatments. The facility and professional providers are responsible for providing medical advice and treatment. Facility and professional providers are independent contractors and are not employees or agents of IBC. If you have a specific medical condition, please consult with your doctor. IBC reserves the right at any time to change or update its Policy Bulletins. © 2008 Independence Blue Cross. All Rights Reserved. Current Procedural Terminology © 2008 American Medical Association. All Rights Reserved.

